Lexogen Expands NGS Services with GCLP-Compliant Workflows
12. August 2026
Vienna, Austria — 12. August 2026 — Lexogen, a specialist in RNA sequencing technologies and next-generation sequencing services, announces the
News & Blog
Read More ›
Pythia BioSciences and Lexogen Partner to Unify Multi-Omics Data Curation and Analytics with Bulk and Single-Cell RNA Sequencing
23. July 2026
Pythia Biosciences and Lexogen recently announced a strategic partnership to empower researchers with deeper biological insights by combining Lexogen’s expertise
Lexogen Featured in Labiotech’s Beyond Biotech Podcast on AI-Driven Drug Discovery
26. May 2026
26.05.2026, Vienna, Austria — A new episode of Beyond Biotech podcast, produced by Labiotech, is now live, featuring Dr. Stéphane
The power of spike-in controls in RNA-Seq
18. March 2026
RNA sequencing (RNA-Seq) is a powerful technique to assess an organism’s whole transcriptome at unprecedented levels of sensitivity and generate
Building one of the World’s Largest Human Liver Functional Genomics Dataset to Date: Inside the Ochre Bio and Lexogen Partnership
15. December 2025
Building a comprehensive, high-resolution dataset reflecting human liver biology requires more than selecting the right technology, it demands a partner
Lexogen Successfully Completes Large-Scale Human Primary Cell Next Gen Sequencing Project with Ochre Bio
25. November 2025
Vienna, Austria – 25.11.2025 Lexogen, a Vienna-based biotech company specialized in RNA transcriptomics technologies and services announces the completion of a large-scale
Lexogen honored as one of Austria’s Top Innovative Companies 2026 by Statista and trend. magazine
11. November 2025
11.11.2025, Vienna, Austria – Lexogen, a recognized expert in the domain of RNA sequencing and transcriptome analysis, has been recognized among
Lexogen Launches miRVEL Profiling Small RNA-Seq Kit for Streamlined and Cost-Efficient sRNA Expression Analysis
16. October 2025
16.10.2025, Vienna, Austria — Lexogen, a leader in RNA sequencing technologies, announces the launch of the miRVEL Profiling Small RNA-Seq
Choosing Between Whole Transcriptome Total RNA-Seq and 3′ mRNA-Seq: A Practical Guide and Comparison
25. September 2025
Every successful RNA-Seq experiment starts with a thorough and meticulous experimental plan. Designing the experiment is key and one of
Webinar: Beyond the Reads: Designing Successful RNA-Seq Experiments and Data Analyses
27. August 2025
Watch the recording What You Will Learn: Join us for an exciting session on best practices and practical tips for
Precision Cancer Vaccines – How RNA- and DNA-Seq shape the future of neoantigen discovery
8. August 2025
Cancer immunotherapy has transformed the landscape of oncology, offering powerful tools that train the body’s own immune system to fight
How RNA Sequencing is Revolutionizing Cancer Research: Bringing Precision Medicine to Cancer Patients
1. July 2025
RNA sequencing (RNA-Seq) has become an indispensable tool for cancer researchers. Unlike traditional methods, RNA-Seq provides a dynamic snapshot of
Categories
Lexogen GmbH
Campus Vienna Biocenter 5
1030 Vienna, Austria
Telephone:
+43 (0) 1 345 1212
Sales support:
+43 (0) 1 345 1212-42
Technical support:
+43 (0) 1 345 1212-41
Working hours: 9:00 – 17:00 (CET)
Fax: +43 (0) 1 345 1212-99
Email: info@lexogen.com
Company number: FN 297318 h
VAT number: ATU63622048
Lexogen, Inc.
51 Autumn Pond Park
Greenland, NH 03840, US
Telephone:
+1-603-431-4300 ext.0
+1-877-Lexogen
(+1-877-539-6436) ext. 0
Sales inquiries:
Northeast and Great Lakes:
+1 312-978-6413
California:
+1 415-726-4318
Rest of the Country:
+1 615-968-3325
Lexogen Newsletter
Subscribe to our mailing list to be among the first to get updates from us!
Copyright © 2026 Lexogen GmbH. All rights reserved | Impressum | Privacy Policy | Terms and Conditions | Whistleblowing
Cart
Product
Product Short Description
PRICE
Product
Product Short Description
PRICE
Product
Product Short Description
PRICE